poisar

Stocks · News reference

Guggenheim Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

Benzinga Newsdesk

Guggenheim analyst Yatin Suneja maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $25 to $22.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

PHAT
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

    Phathom Pharmaceuticals announced that its management team will participate in two major investor conferences in September 2026: the Cantor Global Healthcare Conference on September 9 and the H.C. Wainwright 28th Annual Global Investment Conference on September 15. Both events will feature fireside chats and one-on-one meetings with investors. Live webcasts and 90-day archived recordings will be available on the company's investor relations website.

    PHAT